✕

CTR

pISSN 3022-6783
eISSN 3022-7712

View

Article View

Clin Transplant Res 2024; 38(3): 212-221

Published online September 30, 2024

https://doi.org/10.4285/ctr.24.0031

© The Korean Society for Transplantation

Remdesivir in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis

Zia Navidi1 , Seyed Hamid Pakzad Moghadam1 , Mojgan Mohajeri Iravani2 , Amirhossein Orandi3 , Amirali Orandi4 , Samrand Fattah Ghazi5, Ehsan Fallah6 , Ebadallah Shiri Malekabad7 , Saeed Khorramnia1

1Department of Anesthesiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
2Department of Anesthesiology, Faculty of Paramedical Sciences, AJA University of Medical Sciences, Tehran, Iran
3Department of Anesthesiology, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4Department of Anesthesia and Critical Care, Sina Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5Department of Intensive Care Medicine, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
6Department of Orthopedics, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
7School of Nursing, AJA University of Medical Sciences, Tehran, Iran

Correspondence to: Saeed Khorramnia
Department of Anesthesiology, School of Medicine, Rafsanjan University of Medical Sciences, Khalije Fars Blvd, Pistachio Co. St, Rafsanjan 7718175911, Iran
E-mail: saeedkhorramnia1@gmail.com

Received: June 28, 2024; Revised: August 25, 2024; Accepted: September 11, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The use of remdesivir in solid organ transplant recipients (SOTRs) with coronavirus disease 2019 (COVID-19) has been studied. The present systematic review and analysis aimed to assess its effectiveness in this population.
Methods: A comprehensive search of PubMed, Cochrane Library, Web of Science, Embase, medRxiv, and Google Scholar was conducted to identify relevant articles published up to April 2024. The quality of the included studies was evaluated using the Cochrane assessment tool. Data analysis was performed using the Comprehensive Meta-Analysis software ver. 3.0.
Results: The meta-analysis included seven eligible retrospective studies, involving a total of 574 SOTRs. The findings indicated no significant differences in mortality rate (odds ratio [OR], 1.19; 95% confidence interval [CI], 0.59–2.39), hospitalization rate (OR, 0.69; 95% CI, 0.10–4.79), need for mechanical ventilation (OR, 0.98; 95% CI, 0.44–2.18), or need for oxygen therapy (OR, 3.73; 95% CI, 0.75–18.34) between the groups that received remdesivir and those that did not. However, a statistically significant difference was observed in the rate of intensive care unit admissions between the two groups (OR, 2.39; 95% CI, 1.24–4.57).
Conclusions: Our meta-analysis found that remdesivir offers no clinical benefits to SOTRs infected with COVID-19. Additional high-quality research is required to assess the potential clinical advantages of remdesivir for SOTRs with COVID-19.

Keywords: COVID-19, SARS-CoV-2, Coronavirus, Organ transplantation, Remdesivir

Supplementary information
Supplementary File

Article Tools

Share this article on :

Metrics

Related articles in KJT